What are the recommended treatment options and dosages for onychomycosis?

Onychomycosis Treatment and Dosage

Terbinafine should be your first-line treatment for dermatophyte onychomycosis at 250 mg daily for 6 weeks for fingernails and 12-16 weeks for toenails, as it demonstrates superior efficacy with complete cure rates of 55% versus 26% for itraconazole and significantly lower relapse rates (21-23% versus 48-53%). 1

First-Line Systemic Therapy

Terbinafine (Preferred)

• Dosing: 250 mg daily 1
  • Fingernails: 6 weeks
  • Toenails: 12-16 weeks
• Efficacy: Mycological cure rates of 70% for toenails, complete cure 38-55% 1, 2
• Long-term outcomes: At 5-year follow-up, mycological cure maintained in 46% versus only 13% with itraconazole 1
• Monitoring: Baseline liver function tests and complete blood count recommended, especially in patients with history of heavy alcohol consumption, hepatitis, or hematological abnormalities 1
• Key advantage: Minimal drug-drug interactions (only significant interaction with CYP450 2D6 substrates) 1
• Critical warning: Taste disturbance can be permanent; patients must be counseled 1

Itraconazole (Second-Line Alternative)

• Continuous dosing: 200 mg daily for 12 weeks 1, 3
• Pulse therapy (preferred regimen): 400 mg daily for 1 week per month 1, 3
  • Fingernails: 2 pulses
  • Toenails: 3 pulses
• Efficacy: Mycological cure 54% for toenails, complete cure 14-26% 1, 2
• Absorption: Must be taken with food and acidic pH for optimal absorption 1
• Monitoring: Hepatic function tests required in patients with pre-existing abnormalities, continuous therapy >1 month, or concomitant hepatotoxic drugs 1
• Contraindication: Heart failure 1

Alternative Systemic Options

Fluconazole (Third-Line)

• Dosing: 150-450 mg once weekly 1
  • Fingernails: 3 months minimum
  • Toenails: At least 6 months (optimal 9-12 months for higher cure rates)
• Efficacy: Mycological cure 47-62% for toenails, 89-100% for fingernails 1
• Evidence: Higher doses (450 mg weekly) and longer duration (>6 months) associated with better outcomes 1, 4, 5
• Indication: Useful when terbinafine or itraconazole contraindicated or not tolerated 1
• Advantage: Once-weekly dosing improves compliance; fewer drug interactions than itraconazole 1
• Monitoring: Baseline liver function tests and full blood count; monitor LFTs in high-dose or prolonged therapy 1
• Note: Not FDA-approved for onychomycosis 1

Griseofulvin (Fourth-Line)

• Dosing: 500-1000 mg daily with fatty food 1
  • Fingernails: 6-9 months
  • Toenails: 12-18 months
• Evidence: Lower efficacy and higher relapse rates compared to terbinafine and itraconazole 1, 3
• Use only when: Other agents contraindicated or not tolerated 1

Topical Therapy

Amorolfine

• Dosing: 5% lacquer applied once or twice weekly for 6-12 months 1
• Indication: Superficial and distal onychomycosis 1

Ciclopirox

• Dosing: 8% lacquer applied daily for up to 48 weeks 1
• Indication: Superficial and distal onychomycosis; patients with systemic therapy contraindications 1

Efinaconazole and Tavaborole

• FDA-approved topical options for mild to moderate onychomycosis 6

Pediatric Dosing (Ages 1-12 Years)

Terbinafine (First-Line)

• Weight-based dosing: 1
  • <20 kg: 62.5 mg daily
  • 20-40 kg: 125 mg daily

  • 40 kg: 250 mg daily

• Duration: 6 weeks for fingernails, 12 weeks for toenails
• Monitoring: Baseline LFTs and CBC required (unlicensed in children) 1

Itraconazole (First-Line Alternative)

• Pulse therapy: 5 mg/kg daily for 1 week per month 1
  • Fingernails: 2 pulses
  • Toenails: 3 pulses

Fluconazole (Second-Line)

• Dosing: 3-6 mg/kg once weekly 1
  • Fingernails: 12-16 weeks
  • Toenails: 18-26 weeks

Special Considerations for Candidal Onychomycosis

• Itraconazole is most effective: 400 mg daily for 1 week per month 3
  • Fingernails: 2 pulses
  • Toenails: 3-4 pulses
• Topical therapy: Often sufficient for paronychia-associated infections using imidazole lotion alternating with antibacterial lotion 3

Critical Management Points

Re-evaluation Protocol

• Assess response at 3-6 months after treatment initiation 1
• Provide additional treatment if disease persists 1
• Follow-up period: Minimum 48 weeks, preferably 72 weeks from treatment start to identify relapse 3

Common Pitfalls to Avoid

• Never start treatment without mycological confirmation (microscopy and culture) 3
• Do not use topical monotherapy for extensive disease (>50% nail involvement or matrix involvement) 1
• Avoid itraconazole in heart failure patients 1
• Do not overlook baseline monitoring requirements for hepatotoxicity risk 1
• Warn patients about permanent taste disturbance with terbinafine 1

Treatment Failure Considerations

• Expected failure rates: 20-30% even with optimal therapy 3
• Reassess for: Poor compliance, inadequate absorption, drug interactions, or resistant organisms 1, 7
• Consider combination therapy (systemic plus topical) for refractory cases 1